Immunology Phase 3 Deal Benchmarks — Europe

Understanding Immunology Deal Benchmarks at Phase 3

Phase 3 Immunology licensing deals in Europe territory command a median upfront payment of $225M, with values ranging from $142M at the low end to $327M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the immunology therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $634M to $1.1B, with a median of $880M. Royalty rates for immunology assets at this stage typically fall between 12.2% and 19% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.

The Europe territory applies a 0.25x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating europe rights should calibrate upfront expectations and milestone structures accordingly.